Impact of levetiracetam use in glioblastoma: an individual patient-level meta-analysis assessing overall survival.

ABSTRACT:

Background

Levetiracetam (Lev), an antiepileptic drug (AED), enhances alkylating chemotherapy sensitivity in glioblastoma (GB) by inhibiting MGMT expression. This meta-analysis evaluates Lev's impact on GB treatment by analyzing overall survival of individual patient data (IPD) from published studies.

Methods

IPD was reconstructed using the R package IPDfromKM. Pooled IPD Kaplan-Meier charts of survival stratified by Lev therapy were created using the R package Survminer. One- and two-stage meta-analyses of Lev treatment regarding survival was performed.

Results

Three articles covering 825 patients were included out of 3567 screened records. Lev usage prevalence was 0.36. IPD from 590 IDH wild-type glioblastomas, with a median follow-up of 16.1 months, were utilized.

SUBMITTER: Vychopen M 

PROVIDER: S-EPMC11628436 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature